Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Aug 14, 2015 11:48pm

230 Views

Post# 24020978

RE:Zack Report

Yeah, you're probably right. A successful Phase 3 wouldn't attract any attention from the media, analysts, big pharma, or attract any additional retail investors. And a potential Nasdaq listing along the way wouldn't help with additional exposure or help the stock price at all either. Wow! Sure glad you rely on the uber conservative projections of the Zack report to form your opinions and straighten the rest of us out!

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale